Arca
Skip to content
Tools
Tools

-mab

A monoclonal antibody: a lab-made antibody aimed at one target. WHO used -mab until 2021, with syllables in front naming the target and, until 2017, the species the antibody came from.

  • Drugs ending in -mab: 758
  • Approved somewhere: 150
  • With a US drug page: 134

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-mab
Class
Monoclonal antibodies named under the pre-2021 scheme
Sub-stems
-vetmab
Most common targets
Tubulin (34), PDCD1 (23), EGFR (18), S (15), T cell surface glycoprotein CD3 (13), MS4A1 (13), ERBB2 (11), CD274 (10)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -mab or one of its sub-stems, matched by spelling; those with a US drug page link to it.
Acts on
AbciximabApprovedITGA2B, ITGB3, ITGAV, ITGB3Integrin alpha-IIb/beta-3 inhibitor
AducanumabApprovedAPPAmyloid-beta A4 protein binding agent
AlemtuzumabApprovedCD52CAMPATH-1 antigen inhibitor
AlirocumabApprovedPCSK9Subtilisin/kexin type 9 inhibitor
AmivantamabApprovedEGFR, METEpidermal growth factor receptor erbB1 inhibitor
AnifrolumabApprovedIFNAR1Interferon-alpha/beta receptor alpha chain antagonist
AnsuvimabApprovedGPEnvelope glycoprotein binding agent
AtezolizumabApprovedCD274Programmed cell death 1 ligand 1 inhibitor
AvelumabApprovedCD274Programmed cell death 1 ligand 1 other
BasiliximabApprovedInterleukin-2 receptorInterleukin-2 receptor inhibitor
Belantamab mafodotinApprovedTNFRSF17, TubulinTumor necrosis factor receptor superfamily member 17 binding agent
BelimumabApprovedTNFSF13BTumor necrosis factor ligand superfamily member 13B inhibitor
BenralizumabApprovedIL5RAInterleukin-5 receptor subunit alpha inhibitor
BezlotoxumabApprovedTCDBToxin B inhibitor
BimekizumabApprovedIL17A, IL17FInterleukin 17A inhibitor
BlinatumomabApprovedT cell surface glycoprotein CD3, CD19T cell surface glycoprotein CD3 cross-linking agent
Brentuximab vedotinApprovedTubulin, TNFRSF8Tubulin inhibitor
BrodalumabApprovedIL17RAInterleukin-17 receptor A antagonist
BrolucizumabApprovedVEGFAVascular endothelial growth factor A inhibitor
BurosumabApprovedFGF23Fibroblast growth factor 23 inhibitor
CanakinumabApprovedIL1BInterleukin-1 beta inhibitor
CaplacizumabApprovedVWFvon Willebrand factor inhibitor
CemiplimabApprovedPDCD1Programmed cell death protein 1 inhibitor
Certolizumab pegolApprovedTNFTNF-alpha inhibitor
CetuximabApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
CosibelimabApprovedCD274Programmed cell death 1 ligand 1 inhibitor
CrizanlizumabApprovedSELPP-selectin blocker
CrovalimabApprovedC5Complement C5 inhibitor
DaclizumabApprovedInterleukin-2 receptorInterleukin-2 receptor inhibitor
DaratumumabApprovedCD38Lymphocyte differentiation antigen CD38 inhibitor
DinutuximabApprovedDisialoganglioside GD2Disialoganglioside GD2 binding agent
DonanemabApprovedAPPAmyloid-beta A4 protein disrupting agent
DostarlimabApprovedPDCD1Programmed cell death protein 1 antagonist
DupilumabApprovedIL4RInterleukin-4 receptor subunit alpha antagonist
DurvalumabApprovedCD274Programmed cell death 1 ligand 1 inhibitor
ElotuzumabApprovedSLAMF7SLAM family member 7 inhibitor
ElranatamabApprovedT cell surface glycoprotein CD3, TNFRSF17T cell surface glycoprotein CD3 binding agent
EmapalumabApprovedIFNGInterferon gamma inhibitor
EmicizumabApprovedF10, F9Coagulation factor IX and X other
Enfortumab vedotinApprovedNECTIN4, TubulinNectin-4 binding agent
EpcoritamabApprovedMS4A1, T cell surface glycoprotein CD3B-lymphocyte antigen CD20 binding agent
EptinezumabApprovedCALCA, CALCBCalcitonin gene-related peptide inhibitor
ErenumabApprovedCALCRLCalcitonin gene-related peptide type 1 receptor antagonist
EvinacumabApprovedANGPTL3Angiopoietin-related protein 3 inhibitor
EvolocumabApprovedPCSK9Subtilisin/kexin type 9 inhibitor
FaricimabApprovedANGPT2, VEGFAAngiopoietin-2 inhibitor
FremanezumabApprovedCALCA, CALCBCalcitonin gene-related peptide antagonist
GalcanezumabApprovedCALCA, CALCBCalcitonin gene-related peptide inhibitor
Gemtuzumab ozogamicinApprovedCD33, DNAMyeloid cell surface antigen CD33 binding agent
GlofitamabApprovedMS4A1, T cell surface glycoprotein CD3B-lymphocyte antigen CD20 binding agent
GuselkumabApprovedIL12B, IL23AInterleukin-23 inhibitor
IbalizumabApprovedCD4T-cell surface antigen CD4 inhibitor
IdarucizumabApprovedDabigatranDabigatran sequestering agent
InebilizumabApprovedCD19B-lymphocyte antigen CD19 binding agent
Inotuzumab ozogamicinApprovedCD22, DNACD22 binding agent
IpilimumabApprovedCTLA4Cytotoxic T-lymphocyte protein 4 inhibitor
IsatuximabApprovedCD38Lymphocyte differentiation antigen CD38 inhibitor
IxekizumabApprovedIL17AInterleukin 17A inhibitor
LanadelumabApprovedKLKB1Plasma kallikrein inhibitor
LebrikizumabApprovedIL13Interleukin-13 inhibitor
LecanemabApprovedAPPAmyloid-beta A4 protein inhibitor
Loncastuximab tesirineApprovedCD19, DNAB-lymphocyte antigen CD19 binding agent
MargetuximabApprovedERBB2Receptor protein-tyrosine kinase erbB-2 inhibitor
MarstacimabApprovedTFPITissue factor pathway inhibitor inhibitor
MepolizumabApprovedIL5Interleukin-5 inhibitor
MirikizumabApprovedIL12B, IL23AInterleukin-23 inhibitor
Mirvetuximab soravtansineApprovedFOLR1, TubulinFolate receptor alpha binding agent
MogamulizumabApprovedCCR4C-C chemokine receptor type 4 cross-linking agent
MosunetuzumabApprovedT cell surface glycoprotein CD3, MS4A1T cell surface glycoprotein CD3 binding agent
Moxetumomab pasudotoxApprovedCD22, EEF2CD22 binding agent
NaxitamabApprovedDisialoganglioside GD2Disialoganglioside GD2 binding agent
NecitumumabApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
NemolizumabApprovedIL31RAInterleukin-31 receptor subunit alpha inhibitor
NirsevimabApprovedFFusion glycoprotein F0 inhibitor
NivolumabApprovedPDCD1Programmed cell death protein 1 inhibitor
ObiltoxaximabApprovedPAGAProtective antigen binding agent
ObinutuzumabApprovedMS4A1B-lymphocyte antigen CD20 binding agent
OcrelizumabApprovedMS4A1B-lymphocyte antigen CD20 binding agent
OfatumumabApprovedMS4A1B-lymphocyte antigen CD20 binding agent
OlaratumabApprovedPDGFRAPlatelet-derived growth factor receptor alpha antagonist
PalivizumabApprovedFFusion glycoprotein F0 inhibitor
PanitumumabApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
PembrolizumabApprovedPDCD1Programmed cell death protein 1 inhibitor
Polatuzumab vedotinApprovedCD79B, TubulinB-cell antigen receptor complex-associated protein beta chain binding agent
PozelimabApprovedC5Complement C5 inhibitor
RamucirumabApprovedKDRVascular endothelial growth factor receptor 2 inhibitor
RavulizumabApprovedC5Complement C5 inhibitor
RaxibacumabApprovedPAGAProtective antigen binding agent
ReslizumabApprovedIL5Interleukin-5 inhibitor
RetifanlimabApprovedPDCD1Programmed cell death protein 1 antagonist
RisankizumabApprovedIL12B, IL23AInterleukin-23 inhibitor
RomosozumabApprovedSOSTSclerostin inhibitor
RozanolixizumabApprovedFCGRTIgG receptor FcRn large subunit p51 inhibitor
Sacituzumab govitecanApprovedTACSTD2, TOP1Tumor-associated calcium signal transducer 2 binding agent
SarilumabApprovedIL6RInterleukin-6 receptor alpha subunit antagonist
SatralizumabApprovedIL6R, IL6STIL6Ralpha/GP130 antagonist
SecukinumabApprovedIL17AInterleukin 17A inhibitor
SiltuximabApprovedIL6Interleukin-6 antagonist
SpesolimabApprovedIL1RAP, IL1RL2IL36 receptor antagonist
SutimlimabApprovedC1SComplement C1s inhibitor
TafasitamabApprovedCD19B-lymphocyte antigen CD19 binding agent
TalquetamabApprovedT cell surface glycoprotein CD3, GPRC5DT cell surface glycoprotein CD3 binding agent
TarlatamabApprovedT cell surface glycoprotein CD3, DLL3T cell surface glycoprotein CD3 binding agent
TeclistamabApprovedT cell surface glycoprotein CD3, TNFRSF17T cell surface glycoprotein CD3 binding agent
TeplizumabApprovedCD3ET-cell surface glycoprotein CD3 epsilon chain other
TeprotumumabApprovedIGF1RInsulin-like growth factor I receptor antagonist
TezepelumabApprovedTSLPThymic stromal lymphopoietin inhibitor
TildrakizumabApprovedIL12B, IL23AInterleukin-23 inhibitor
TislelizumabApprovedPDCD1Programmed cell death protein 1 inhibitor
Tisotumab vedotinApprovedTubulin, F3Tubulin inhibitor
ToripalimabApprovedPDCD1Programmed cell death protein 1 antagonist
TralokinumabApprovedIL13Interleukin-13 inhibitor
TremelimumabApprovedCTLA4Cytotoxic T-lymphocyte protein 4 inhibitor
UblituximabApprovedMS4A1B-lymphocyte antigen CD20 binding agent
VedolizumabApprovedITGA4, ITGB7Integrin alpha-4/beta-7 inhibitor
ZanidatamabApprovedERBB2Receptor protein-tyrosine kinase erbB-2 inhibitor
ZenocutuzumabApprovedERBB2, ERBB3ErbB-2/ErbB-3 heterodimer inhibitor
ZolbetuximabApprovedCLDN18Claudin-18 binding agent
ApitegromabPhase 3MSTNGrowth/differentiation factor 8 inhibitor
ClesrovimabPhase 3FFusion glycoprotein F0 inhibitor
Datopotamab deruxtecanPhase 3TACSTD2, TOP1Tumor-associated calcium signal transducer 2 binding agent
DepemokimabPhase 3IL5Interleukin-5 inhibitor
GaretosmabPhase 3INHBAInhibin beta A chain inhibitor
Ibritumomab tiuxetanPhase 3——
LinvoseltamabPhase 3——
NarsoplimabPhase 3MASP2Mannan-binding lectin serine protease 2 inhibitor
NipocalimabPhase 3FCGRTIgG receptor FcRn large subunit p51 antagonist
PenpulimabPhase 3PDCD1Programmed cell death protein 1 inhibitor
Telisotuzumab vedotinPhase 3Tubulin, METTubulin inhibitor
AxatilimabPhase 2CSF1RMacrophage colony stimulating factor receptor inhibitor
SibeprenlimabPhase 2TNFSF13Tumor necrosis factor ligand superfamily member 13 inhibitor
Pivekimab sunirinePhase 1IL3RA, DNAInterleukin-3 receptor subunit alpha binding agent
Capromab pendetide——Diagnostic agent
Imciromab pentetate——Diagnostic (monoclonal antibody that is labelled with Indium (111In) for imaging)
AdalimumabApprovedTNFTNF-alpha inhibitor
ArcitumomabApprovedCEACAM5Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
AtoltivimabApprovedGPEnvelope glycoprotein inhibitor
BesilesomabApproved—Diagnostic agent
BevacizumabApprovedVEGFAVascular endothelial growth factor A inhibitor
Bevacizumab gammaApprovedVEGFAVascular endothelial growth factor A binding agent
CatumaxomabApprovedT cell surface glycoprotein CD3, EPCAMT cell surface glycoprotein CD3 cross-linking agent
ConcizumabApprovedTFPITissue factor pathway inhibitor inhibitor
DenosumabApprovedTNFSF11Tumor necrosis factor ligand superfamily member 11 inhibitor
Dinutuximab betaApprovedDisialoganglioside GD2Disialoganglioside GD2 inhibitor
EculizumabApprovedC5Complement C5 inhibitor
EfalizumabApprovedITGAL, ITGB2Integrin alpha-L/beta-2 (LFA-1) inhibitor
GolimumabApprovedTNFTNF-alpha inhibitor
IgovomabApprovedMUC16Mucin-16 binding agent
InfliximabApprovedTNFTNF-alpha inhibitor
MaftivimabApprovedGPEnvelope glycoprotein inhibitor
NatalizumabApprovedITGA4, ITGB7, ITGA4, ITGB1Integrin alpha-4/beta-7 inhibitor
OdesivimabApprovedGPEnvelope glycoprotein inhibitor
OmalizumabApprovedIGHEIg epsilon chain C region inhibitor
PertuzumabApprovedERBB2Receptor protein-tyrosine kinase erbB-2 inhibitor
RanibizumabApprovedVEGFAVascular endothelial growth factor A inhibitor
RegdanvimabApprovedSSpike glycoprotein inhibitor
RituximabApprovedMS4A1B-lymphocyte antigen CD20 binding agent
SotrovimabApprovedSSpike glycoprotein inhibitor
SugemalimabApprovedCD274Programmed cell death 1 ligand 1 binding agent
SulesomabApproved—Diagnostic agent
TocilizumabApprovedIL6RInterleukin-6 receptor alpha subunit inhibitor
TrastuzumabApprovedERBB2Receptor protein-tyrosine kinase erbB-2 inhibitor
Trastuzumab deruxtecanApprovedERBB2, TOP1Receptor protein-tyrosine kinase erbB-2 binding agent
Trastuzumab emtansineApprovedERBB2, TubulinReceptor protein-tyrosine kinase erbB-2 binding agent
UstekinumabApprovedIL12A, IL12B, IL12B, IL23AInterleukin-12 inhibitor
VotumumabApproved—Diagnostic agent
AbelacimabPhase 3F11Coagulation factor XI inhibitor
AdebrelimabPhase 3CD274Programmed cell death 1 ligand 1 inhibitor
AlnuctamabPhase 3——
AmlitelimabPhase 3TNFSF4Tumor necrosis factor ligand superfamily member 4 inhibitor
AmubarvimabPhase 3SSpike glycoprotein inhibitor
AndecaliximabPhase 3MMP9Matrix metalloproteinase 9 inhibitor
AnselamimabPhase 3——
AstegolimabPhase 3IL1RAP, IL1RL1IL-33 receptor (ST2) inhibitor
BalstilimabPhase 3PDCD1Programmed cell death protein 1 antagonist
BamlanivimabPhase 3SSpike glycoprotein inhibitor
BapineuzumabPhase 3APPAmyloid-beta A4 protein binding agent
BarzolvolimabPhase 3——
BatoclimabPhase 3FCGRTIgG receptor FcRn large subunit p51 inhibitor
BavituximabPhase 3PhosphatidylserinePhosphatidylserine inhibitor
BegelomabPhase 3DPP4Dipeptidyl peptidase IV inhibitor
BentracimabPhase 3TicagrelorTicagrelor sequestering agent
BermekimabPhase 3IL1AInterleukin-1 alpha inhibitor
BimagrumabPhase 3ACVR2BActivin receptor type-2B antagonist
BirtamimabPhase 3Light chain aggregatesLight chain aggregates inhibitor
BococizumabPhase 3PCSK9Subtilisin/kexin type 9 inhibitor
BrazikumabPhase 3IL12B, IL23AInterleukin-23 inhibitor
BriakinumabPhase 3IL12B, IL23A, IL12A, IL12BInterleukin-23 inhibitor
CadonilimabPhase 3PDCD1, CTLA4Programmed cell death protein 1 inhibitor
CamrelizumabPhase 3PDCD1Programmed cell death protein 1 antagonist
CarotuximabPhase 3ENGEndoglin inhibitor
CasirivimabPhase 3SSpike glycoprotein inhibitor
CendakimabPhase 3IL13Interleukin-13 inhibitor
CertolizumabPhase 3——
CetrelimabPhase 3PDCD1Programmed cell death protein 1 inhibitor
CilgavimabPhase 3SSpike glycoprotein blocker
CrenezumabPhase 3APPAmyloid-beta A4 protein inhibitor
Dapirolizumab pegolPhase 3CD40LGCD40 ligand inhibitor
Depatuxizumab mafodotinPhase 3EGFR, TubulinEpidermal growth factor receptor erbB1 binding agent
Disitamab vedotinPhase 3ERBB2, TubulinReceptor tyrosine-protein kinase erbB-2 binding agent
DivozilimabPhase 3——
DomvanalimabPhase 3TIGITT-cell immunoreceptor with Ig and ITIM domains inhibitor
EbdarokimabPhase 3IL12A, IL12B, IL12B, IL23AInterleukin-12 inhibitor
EdrecolomabPhase 3EPCAMEpithelial cell adhesion molecule cross-linking agent
EmactuzumabPhase 3CSF1RMacrophage colony stimulating factor receptor inhibitor
EnvafolimabPhase 3CD274Programmed cell death 1 ligand 1 binding agent
EpratuzumabPhase 3CD22CD22 inhibitor
ErfonrilimabPhase 3CTLA4, CD274Cytotoxic T-lymphocyte protein 4 inhibitor
EtesevimabPhase 3SSpike glycoprotein inhibitor
EtrolizumabPhase 3ITGB7Integrin beta-7 antagonist
FarletuzumabPhase 3FOLR1Folate receptor alpha inhibitor
FasinumabPhase 3NGFBeta-nerve growth factor inhibitor
FavezelimabPhase 3LAG3Lymphocyte activation gene 3 protein inhibitor
FelzartamabPhase 3CD38Lymphocyte differentiation antigen CD38 inhibitor
FianlimabPhase 3LAG3Lymphocyte activation gene 3 protein inhibitor
FiclatuzumabPhase 3HGFHepatocyte growth factor inhibitor
FigitumumabPhase 3IGF1RInsulin-like growth factor I receptor antagonist
FinotonlimabPhase 3PDCD1Programmed cell death protein 1 inhibitor
FrexalimabPhase 3——
FulranumabPhase 3NGFBeta-nerve growth factor inhibitor
GaliximabPhase 3CD80T-lymphocyte activation antigen CD80 inhibitor
GantenerumabPhase 3APPAmyloid-beta A4 protein binding agent
GefurulimabPhase 3——
GemtuzumabPhase 3CD33Myeloid cell surface antigen CD33 binding agent
GevokizumabPhase 3IL1BInterleukin-1 beta negative allosteric modulator
GirentuximabPhase 3CA9Carbonic anhydrase IX other
GumokimabPhase 3——
IanalumabPhase 3TNFRSF13CTumor necrosis factor receptor superfamily member 13C binding agent
Ifinatamab deruxtecanPhase 3——
ImdevimabPhase 3SSpike glycoprotein inhibitor
InolimomabPhase 3IL2RAInterleukin-2 receptor alpha chain antagonist
InotuzumabPhase 3CD22CD22 binding agent
ItepekimabPhase 3IL33Interleukin-33 inhibitor
ItolizumabPhase 3CD6T-cell differentiation antigen CD6 inhibitor
IvonescimabPhase 3——
LampalizumabPhase 3CFDComplement factor D inhibitor
LatozinemabPhase 3——
LemzoparlimabPhase 3——
LenzilumabPhase 3CSF2Granulocyte-macrophage colony-stimulating factor inhibitor
LeronlimabPhase 3CCR5C-C chemokine receptor type 5 antagonist
LevilimabPhase 3IL6RInterleukin-6 receptor alpha subunit inhibitor
LigelizumabPhase 3IGHEIg epsilon chain C region inhibitor
LintuzumabPhase 3CD33Myeloid cell surface antigen CD33 other
LirentelimabPhase 3SIGLEC8Sialic acid-binding Ig-like lectin 8 inhibitor
LitifilimabPhase 3CLEC4CC-type lectin domain family 4 member C inhibitor
LutikizumabPhase 3IL1A, IL1BInterleukin-1 alpha inhibitor
MagrolimabPhase 3CD47Leukocyte surface antigen CD47 inhibitor
MitumomabPhase 3Ganglioside GD3Ganglioside GD3 other
MonalizumabPhase 3KLRC1NKG2-A/NKG2-B type II integral membrane protein inhibitor
MotavizumabPhase 3FFusion glycoprotein F0 inhibitor
MupadolimabPhase 3——
NimotuzumabPhase 3EGFREpidermal growth factor receptor erbB1 inhibitor
ObexelimabPhase 3CD19, FCGR2BB-lymphocyte antigen CD19 inhibitor
OciperlimabPhase 3TIGITT-cell immunoreceptor with Ig and ITIM domains inhibitor
OdronextamabPhase 3MS4A1, T cell surface glycoprotein CD3B-lymphocyte antigen CD20 binding agent
OleclumabPhase 3NT5E5'-nucleotidase inhibitor
OlokizumabPhase 3IL6Interleukin-6 inhibitor
OnartuzumabPhase 3METHepatocyte growth factor receptor antagonist
OngericimabPhase 3PCSK9Subtilisin/kexin type 9 inhibitor
OntamalimabPhase 3MADCAM1Mucosal addressin cell adhesion molecule-1 inhibitor
Oportuzumab monatoxPhase 3EPCAM, EEF2Epithelial cell adhesion molecule binding agent
OregovomabPhase 3MUC16Mucin-16 other
OtelixizumabPhase 3CD3ET-cell surface glycoprotein CD3 epsilon chain binding agent
OtilimabPhase 3CSF2Granulocyte-macrophage colony-stimulating factor inhibitor
PamrevlumabPhase 3CCN2Connective tissue growth factor inhibitor
PatritumabPhase 3ERBB3Receptor tyrosine-protein kinase erbB-3 inhibitor
Patritumab deruxtecanPhase 3ERBB3, TOP1Receptor tyrosine-protein kinase erbB-3 binding agent
PexelizumabPhase 3C5Complement C5 inhibitor
ProlgolimabPhase 3——
PucotenlimabPhase 3PDCD1Programmed cell death protein 1 inhibitor
PulocimabPhase 3——
QuavonlimabPhase 3CTLA4Cytotoxic T-lymphocyte protein 4 inhibitor
RacotumomabPhase 3Ganglioside GM3 (NeuGcGM3)Ganglioside GM3 (NeuGcGM3) inhibitor
RecaticimabPhase 3——
RelatlimabPhase 3LAG3Lymphocyte activation gene 3 protein inhibitor
RilotumumabPhase 3HGFHepatocyte growth factor inhibitor
RipertamabPhase 3——
RocatinlimabPhase 3TNFRSF4Tumor necrosis factor receptor superfamily member 4 antagonist
RomlusevimabPhase 3SSpike glycoprotein inhibitor
Rovalpituzumab tesirinePhase 3DLL3, DNADelta-like protein 3 binding agent
SabatolimabPhase 3HAVCR2Hepatitis A virus cellular receptor 2 inhibitor
Sacituzumab tirumotecanPhase 3——
SasanlimabPhase 3PDCD1Programmed cell death protein 1 antagonist
SemzuvolimabPhase 3CD4T-cell surface antigen CD4 inhibitor
SerplulimabPhase 3PDCD1Programmed cell death protein 1 antagonist
SetrusumabPhase 3SOSTSclerostin inhibitor
SintilimabPhase 3PDCD1Programmed cell death protein 1 antagonist
SirukumabPhase 3IL6Interleukin-6 inhibitor
SocazolimabPhase 3CD274Programmed cell death 1 ligand 1 inhibitor
SolanezumabPhase 3APPAmyloid-beta A4 protein binding agent
SpartalizumabPhase 3PDCD1Programmed cell death protein 1 antagonist
SuptavumabPhase 3FFusion glycoprotein F0 inhibitor
SurzebiclimabPhase 3——
TabalumabPhase 3TNFSF13BTumor necrosis factor ligand superfamily member 13B inhibitor
TafolecimabPhase 3PCSK9Subtilisin/kexin type 9 inhibitor
TanezumabPhase 3NGFBeta-nerve growth factor inhibitor
TifcemalimabPhase 3——
TiragolumabPhase 3TIGITT-cell immunoreceptor with Ig and ITIM domains inhibitor
TixagevimabPhase 3SSpike glycoprotein blocker
TositumomabPhase 3MS4A1B-lymphocyte antigen CD20 binding agent
Tositumomab 131IPhase 3MS4A1B-lymphocyte antigen CD20 binding agent
TozorakimabPhase 3——
Trastuzumab duocarmazinePhase 3ERBB2, DNAReceptor protein-tyrosine kinase erbB-2 binding agent
Trastuzumab envedotinPhase 3——
Trastuzumab vedotinPhase 3——
Tusamitamab ravtansinePhase 3CEACAM5, TubulinCarcinoembryonic antigen-related cell adhesion molecule 5 binding agent
UtomilumabPhase 3TNFRSF9Tumor necrosis factor receptor superfamily member 9 agonist
VibostolimabPhase 3TIGITT-cell immunoreceptor with Ig and ITIM domains antagonist
VilobelimabPhase 3C5Complement C5 inhibitor
VisilizumabPhase 3CD3ET-cell surface glycoprotein CD3 epsilon chain inhibitor
VunakizumabPhase 3IL17AInterleukin 17A inhibitor
ZalutumumabPhase 3EGFREpidermal growth factor receptor erbB1 antagonist
ZanolimumabPhase 3CD4T-cell surface antigen CD4 other
ZimberelimabPhase 3PDCD1Programmed cell death protein 1 inhibitor
AbagovomabPhase 2MUC16Mucin-16 other
AbituzumabPhase 2ITGAV, ITGB1, ITGAV, ITGB3, ITGAV, ITGB5, ITGAV, ITGB6 and 1 moreIntegrin alpha-V/beta-1 inhibitor
AbrilumabPhase 2ITGA4, ITGB7Integrin alpha-4/beta-7 inhibitor
AcasunlimabPhase 2——
AcrixolimabPhase 2——
Adalimumab fosimdesonidePhase 2——
AdecatumumabPhase 2EPCAMEpithelial cell adhesion molecule inhibitor
AdintrevimabPhase 2SSpike glycoprotein inhibitor
AfelimomabPhase 2TNFTNF-alpha inhibitor
Alemtuzumab betaPhase 2CD52CAMPATH-1 antigen binding agent
AmatuximabPhase 2MSLNMesothelin inhibitor
Anetumab ravtansinePhase 2MSLN, TubulinMesothelin binding agent
AnrukinzumabPhase 2IL13Interleukin-13 inhibitor
AnumigilimabPhase 2CSF3RGranulocyte colony stimulating factor receptor antagonist
ApolizumabPhase 2Human leukocyte antigen DR beta chainHuman leukocyte antigen DR beta chain inhibitor
AscrinvacumabPhase 2ACVRL1Serine/threonine-protein kinase receptor R3 inhibitor
AvdoralimabPhase 2C5AR1C5a anaphylatoxin chemotactic receptor inhibitor
Basiliximab sarotalocanPhase 2——
BebtelovimabPhase 2SSpike glycoprotein inhibitor
BemarituzumabPhase 2FGFR2, FCGR3AFibroblast growth factor receptor 2 inhibitor
BepranemabPhase 2MAPTMicrotubule-associated protein tau inhibitor
BertilimumabPhase 2CCL11Eotaxin inhibitor
BetfisolimabPhase 2——
BleselumabPhase 2CD40Tumor necrosis factor receptor superfamily member 5 inhibitor
BlosozumabPhase 2SOSTSclerostin inhibitor
BoserolimabPhase 2——
BotensilimabPhase 2——
BudigalimabPhase 2PDCD1Programmed cell death protein 1 inhibitor
BurfiralimabPhase 2——
CabiralizumabPhase 2CSF1RMacrophage colony stimulating factor receptor antagonist
Camidanlumab tesirinePhase 2IL2RA, DNAInterleukin-2 receptor alpha chain binding agent
CamoteskimabPhase 2IL18Interleukin-18 cross-linking agent
Cantuzumab ravtansinePhase 2MUC1, TubulinMucin-1 binding agent
CarlumabPhase 2CCL2C-C motif chemokine 2 inhibitor
Cetuximab betaPhase 2——
CevostamabPhase 2——
CifurtilimabPhase 2——
CinpanemabPhase 2SNCAAlpha-synuclein inhibitor
CirmtuzumabPhase 2ROR1Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor
CixutumumabPhase 2IGF1RInsulin-like growth factor I receptor antagonist
ClazakizumabPhase 2IL6Interleukin-6 inhibitor
CobolimabPhase 2HAVCR2Hepatitis A virus cellular receptor 2 inhibitor
CodrituzumabPhase 2Ganglioside GD3, GPC3Ganglioside GD3 other
Coltuximab ravtansinePhase 2CD19, TubulinB-lymphocyte antigen CD19 binding agent
CosfroviximabPhase 2GPEnvelope glycoprotein inhibitor
CusatuzumabPhase 2CD70CD70 antigen inhibitor
DacetuzumabPhase 2CD40Tumor necrosis factor receptor superfamily member 5 inhibitor
DalotuzumabPhase 2IGF1RInsulin-like growth factor I receptor antagonist
DaxdilimabPhase 2LILRA4Leukocyte immunoglobulin-like receptor subfamily A member 4 inhibitor
DemcizumabPhase 2DLL4Delta-like protein 4 inhibitor
Denintuzumab mafodotinPhase 2CD19, TubulinB-lymphocyte antigen CD19 binding agent
DepatuxizumabPhase 2EGFREpidermal growth factor receptor erbB1 inhibitor
DetumomabPhase 2—Unknown
DezamizumabPhase 2APCSSerum amyloid P-component inhibitor
DilpacimabPhase 2——
DiridavumabPhase 2HAHemagglutinin inhibitor
DomagrozumabPhase 2MSTNGrowth/differentiation factor 8 inhibitor
DrozitumabPhase 2TNFRSF10BTumor necrosis factor receptor superfamily member 10B agonist
DuligotuzumabPhase 2EGFR, ERBB3Epidermal growth factor receptor erbB1 inhibitor
DusigitumabPhase 2IGF1, IGF2Insulin-like growth factor I inhibitor
EcromeximabPhase 2Ganglioside GD3Ganglioside GD3 other
EfungumabPhase 2HSP90Heat shock protein 90 homolog inhibitor
EldelumabPhase 2CXCL10C-X-C motif chemokine 10 inhibitor
ElezanumabPhase 2RGMARepulsive guidance molecule A inhibitor
EmibetuzumabPhase 2METHepatocyte growth factor receptor inhibitor
EnibarcimabPhase 2ADMADM stabiliser
EnoblituzumabPhase 2CD276CD276 antigen cross-linking agent
EnokizumabPhase 2IL9Interleukin-9 inhibitor
ErtumaxomabPhase 2ERBB2, CD3EReceptor protein-tyrosine kinase erbB-2 cross-linking agent
EtaracizumabPhase 2ITGAV, ITGB3Integrin alpha-V/beta-3 antagonist
EtigilimabPhase 2TIGITT-cell immunoreceptor with Ig and ITIM domains inhibitor
EtokimabPhase 2IL33Interleukin-33 binding agent
ExbivirumabPhase 2SMajor surface antigen binding agent
EzabenlimabPhase 2——
Farletuzumab ecteribulinPhase 2——
FazpilodemabPhase 2FGF1, KLBFGF1/KLB agonist
FeladilimabPhase 2ICOSInducible T-cell costimulator agonist
FezakinumabPhase 2IL22Interleukin-22 inhibitor
FiztasovimabPhase 2——
FletikumabPhase 2IL20Interleukin-20 inhibitor
FlotetuzumabPhase 2IL3RA, T cell surface glycoprotein CD3Interleukin-3 receptor subunit alpha binding agent
FontolizumabPhase 2IFNGInterferon gamma inhibitor
ForalumabPhase 2T cell surface glycoprotein CD3T cell surface glycoprotein CD3 inhibitor
FresolimumabPhase 2TGFB1, TGFB2, TGFB3Transforming growth factor beta-1 inhibitor
FrovocimabPhase 2PCSK9Subtilisin/kexin type 9 inhibitor
FutuximabPhase 2EGFREpidermal growth factor receptor erbB1 antagonist
GalegenimabPhase 2——
GancotamabPhase 2ERBB2, DNA, TOP2AReceptor protein-tyrosine kinase erbB-2 binding agent
GanitumabPhase 2IGF1RInsulin-like growth factor I receptor antagonist
GavilimomabPhase 2BSGBasigin other
GedivumabPhase 2HAHemagglutinin inhibitor
GimsilumabPhase 2CSF2Granulocyte-macrophage colony-stimulating factor inhibitor
Glembatumumab vedotinPhase 2GPNMB, TubulinTransmembrane glycoprotein NMB binding agent
GlenzocimabPhase 2GP6Platelet glycoprotein VI (GPVI) inhibitor
GolocdacimabPhase 2——
GosuranemabPhase 2MAPTMicrotubule-associated protein tau inhibitor
IcrucumabPhase 2FLT1Vascular endothelial growth factor receptor 1 antagonist
IeramilimabPhase 2LAG3Lymphocyte activation gene 3 protein inhibitor
IfinatamabPhase 2——
ImgatuzumabPhase 2EGFR, FCGR3AEpidermal growth factor receptor erbB1 antagonist
ImsidolimabPhase 2IL1RAP, IL1RL2IL36 receptor antagonist
InclacumabPhase 2SELPP-selectin antagonist
Indusatumab vedotinPhase 2Tubulin, GUCY2CTubulin inhibitor
InezetamabPhase 2——
IntetumumabPhase 2ITGAV, ITGB3, ITGAV, ITGB5Integrin alpha-V/beta-3 antagonist
IratumumabPhase 2TNFRSF8Tumor necrosis factor receptor superfamily member 8 other
IscalimabPhase 2CD40Tumor necrosis factor receptor superfamily member 5 inhibitor
Ispectamab debotansinePhase 2——
Ispectamab tazidePhase 2——
IstiratumabPhase 2ERBB3, IGF1RReceptor tyrosine-protein kinase erbB-3 inhibitor
IvuxolimabPhase 2TNFRSF4Tumor necrosis factor receptor superfamily member 4 agonist
IzalontamabPhase 2——
Izalontamab brengitecanPhase 2——
IzuralimabPhase 2——
LacutamabPhase 2KIR3DL2Killer cell immunoglobulin-like receptor 3DL2 antagonist
Ladiratuzumab vedotinPhase 2Tubulin, SLC39A6Tubulin inhibitor
LandogrozumabPhase 2MSTNGrowth/differentiation factor 8 inhibitor
LarcaviximabPhase 2GPEnvelope glycoprotein inhibitor
LenvervimabPhase 2——
LesabelimabPhase 2——
LibivirumabPhase 2SMajor surface antigen binding agent
LicaminlimabPhase 2——
Lifastuzumab vedotinPhase 2Tubulin, SLC34A2Tubulin inhibitor
LirilumabPhase 2KIR2DL1, KIR2DL2, KIR2DL3Killer cell immunoglobulin-like receptor 2DL1 inhibitor
LivmoniplimabPhase 2——
Lorvotuzumab mertansinePhase 2NCAM1, TubulinNeural cell adhesion molecule 1 binding agent
Lulizumab pegolPhase 2CD28T-cell-specific surface glycoprotein CD28 antagonist
LumiliximabPhase 2FCER2Immunoglobulin epsilon Fc receptor antagonist
LusvertikimabPhase 2——
MapatumumabPhase 2TNFRSF10ATRAIL receptor-1 agonist
MatuzumabPhase 2EGFREpidermal growth factor receptor erbB1 inhibitor
MavrilimumabPhase 2CSF2RA, CSF2RBGranulocyte-macrophage colony-stimulating factor receptor antagonist
MecbotamabPhase 2——
Mecbotamab vedotinPhase 2AXL, TubulinTyrosine-protein kinase receptor UFO binding agent
MelrilimabPhase 2——
MezagitamabPhase 2CD38Lymphocyte differentiation antigen CD38 binding agent
MibavademabPhase 2LEPRLeptin receptor agonist
MurlentamabPhase 2——
NamilumabPhase 2CSF2Granulocyte-macrophage colony-stimulating factor inhibitor
Naptumomab estafenatoxPhase 2TPBGTrophoblast glycoprotein other
NeihulizumabPhase 2SELPLGP-selectin glycoprotein ligand 1 inhibitor
NesvacumabPhase 2ANGPT2Angiopoietin-2 inhibitor
NimacimabPhase 2CNR1Cannabinoid CB1 receptor negative allosteric modulator
OlendalizumabPhase 2C5Complement C5 inhibitor
OlinvacimabPhase 2KDRVascular endothelial growth factor receptor 2 inhibitor
OntuxizumabPhase 2CD248Endosialin inhibitor
OpicinumabPhase 2LINGO1Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor
OrdesekimabPhase 2IL15Interleukin-15 inhibitor
OrilanolimabPhase 2FCGRTIgG receptor FcRn large subunit p51 antagonist
OsemitamabPhase 2——
OxelumabPhase 2TNFSF4Tumor necrosis factor ligand superfamily member 4 inhibitor
OzanezumabPhase 2RTN4Reticulon-4 inhibitor
OzoralizumabPhase 2TNFTNF-alpha inhibitor
OzuriftamabPhase 2——
Ozuriftamab vedotinPhase 2——
PacmilimabPhase 2CD274Programmed cell death 1 ligand 1 binding agent
PagibaximabPhase 2Lipoteichoic acidLipoteichoic acid inhibitor
ParsatuzumabPhase 2EGFL7Epidermal growth factor-like protein 7 inhibitor
PascolizumabPhase 2IL4Interleukin-4 inhibitor
PateclizumabPhase 2LTATNF-beta inhibitor
PelgifatamabPhase 2——
PepinemabPhase 2SEMA4DSemaphorin-4D inhibitor
PeresolimabPhase 2——
Pertuzumab zuvotolimodPhase 2——
PidilizumabPhase 2PDCD1Programmed cell death protein 1 inhibitor
PimivalimabPhase 2PDCD1Programmed cell death protein 1 inhibitor
PimurutamabPhase 2EGFREpidermal growth factor receptor erbB1 inhibitor
PlaculumabPhase 2TNFTNF-alpha inhibitor
PlamotamabPhase 2——
PlonmarlimabPhase 2CSF2Granulocyte-macrophage colony-stimulating factor antagonist
PlozalizumabPhase 2CCR2C-C chemokine receptor type 2 inhibitor
PlutavimabPhase 2——
PonezumabPhase 2APPAmyloid-beta A4 protein binding agent
PorgaviximabPhase 2GPEnvelope glycoprotein inhibitor
Praluzatamab ravtansinePhase 2ALCAM, TubulinCD166 antigen binding agent
PrasinezumabPhase 2SNCAAlpha-synuclein binding agent
QuetmolimabPhase 2CX3CL1Fractalkine inhibitor
QuilizumabPhase 2IGHEIg epsilon chain C region inhibitor
QuisovalimabPhase 2TNFSF14Tumor necrosis factor ligand superfamily member 14 inhibitor
RagifilimabPhase 2TNFRSF18Tumor necrosis factor receptor superfamily member 18 agonist
RavagalimabPhase 2CD40LGCD40 ligand antagonist
RefanezumabPhase 2MAGMyelin-associated glycoprotein inhibitor
RemtolumabPhase 2TNF, IL17ATNF-alpha inhibitor
ReozalimabPhase 2——
RinucumabPhase 2PDGFRBPlatelet-derived growth factor receptor beta inhibitor
RobatumumabPhase 2IGF1RInsulin-like growth factor I receptor antagonist
RomilkimabPhase 2IL4, IL13Interleukin-4 inhibitor
RontalizumabPhase 2Interferon alphaInterferon alpha inhibitor
RosnilimabPhase 2——
RuplizumabPhase 2CD40LGCD40 ligand inhibitor
SemorinemabPhase 2MAPTMicrotubule-associated protein tau inhibitor
SeribantumabPhase 2ERBB3Receptor tyrosine-protein kinase erbB-3 antagonist
SevirumabPhase 2GHEnvelope glycoprotein H inhibitor
SifalimumabPhase 2Interferon alphaInterferon alpha inhibitor
SimtuzumabPhase 2LOXL2Lysyl oxidase homolog 2 inhibitor
SiplizumabPhase 2CD2T-cell surface antigen CD2 inhibitor
SonepcizumabPhase 2Sphingosine 1-phosphateSphingosine 1-phosphate inhibitor
SotigalimabPhase 2CD40Tumor necrosis factor receptor superfamily member 5 agonist
SuvratoxumabPhase 2HLYAlpha-hemolysin inhibitor
TalacotuzumabPhase 2IL3RAInterleukin-3 receptor subunit alpha binding agent
Tarcocimab tedromerPhase 2——
TebotelimabPhase 2LAG3, PDCD1Lymphocyte activation gene 3 protein inhibitor
TelazorlimabPhase 2TNFRSF4Tumor necrosis factor receptor superfamily member 4 antagonist
Telimomab aritoxPhase 2CD5, 80S RibosomeT-cell surface glycoprotein CD5 binding agent
Telisotuzumab adizutecanPhase 2——
TemelimabPhase 2ERVW-1Syncytin-1 inhibitor
TeropavimabPhase 2——
TesidolumabPhase 2C5Complement C5 binding agent
TesnatilimabPhase 2——
TibulizumabPhase 2TNFSF13B, IL17ATumor necrosis factor ligand superfamily member 13B inhibitor
TigatuzumabPhase 2TNFRSF10BTumor necrosis factor receptor superfamily member 10B agonist
TilavonemabPhase 2MAPTMicrotubule-associated protein tau inhibitor
TorudokimabPhase 2IL33Interleukin-33 inhibitor
TovetumabPhase 2PDGFRAPlatelet-derived growth factor receptor alpha inhibitor
Trastuzumab botidotinPhase 2ERBB2, TubulinReceptor tyrosine-protein kinase erbB-2 binding agent
Trastuzumab brengitecanPhase 2——
Trastuzumab corixetanPhase 2——
Trastuzumab imbotolimodPhase 2——
Trastuzumab pamirtecanPhase 2——
Trastuzumab rezetecanPhase 2——
TregalizumabPhase 2CD4T-cell surface antigen CD4 agonist
TrevogrumabPhase 2MSTNGrowth/differentiation factor 8 inhibitor
Tucotuzumab celmoleukinPhase 2EPCAMEpithelial cell adhesion molecule other
UnasnemabPhase 2RGMARepulsive guidance molecule A inhibitor
UpanovimabPhase 2——
UrelumabPhase 2TNFRSF9Tumor necrosis factor receptor superfamily member 9 agonist
VanucizumabPhase 2VEGFA, ANGPT2Vascular endothelial growth factor A inhibitor
VarlilumabPhase 2CD27CD27 antigen agonist
VatelizumabPhase 2ITGA2Integrin alpha-2 antagonist
VeltuzumabPhase 2MS4A1B-lymphocyte antigen CD20 binding agent
VibecotamabPhase 2——
VisugromabPhase 2——
VixarelimabPhase 2OSMROncostatin-M-specific receptor subunit beta inhibitor
VobarilizumabPhase 2IL6RInterleukin-6 receptor alpha subunit inhibitor
VobramitamabPhase 2——
Vobramitamab duocarmazinePhase 2——
VolagidemabPhase 2GCGRGlucagon receptor inhibitor
VolociximabPhase 2ITGA5, ITGB1Integrin alpha-5/beta-1 antagonist
VonlerolizumabPhase 2——
VopratelimabPhase 2ICOSInducible T-cell costimulator agonist
VudalimabPhase 2——
XentuzumabPhase 2IGF1, IGF2Insulin-like growth factor I inhibitor
ZagotenemabPhase 2MAPTMicrotubule-associated protein tau inhibitor
ZalifrelimabPhase 2CTLA4Cytotoxic T-lymphocyte protein 4 inhibitor
ZansecimabPhase 2ANGPT2Angiopoietin-2 inhibitor
ZinlirvimabPhase 2ENVEnvelope protein inhibitor
AcapatamabPhase 1——
Aprutumab ixadotinPhase 1FGFR2, TubulinFibroblast growth factor receptor 2 binding agent
AtinumabPhase 1RTN4Reticulon-4 inhibitor
AvizakimabPhase 1——
Azintuxizumab vedotinPhase 1Tubulin, SLAMF7Tubulin inhibitor
BafisontamabPhase 1MET, EGFRHepatocyte growth factor receptor inhibitor
BarecetamabPhase 1——
BavunalimabPhase 1——
BelantamabPhase 1——
BeludavimabPhase 1——
BexmarilimabPhase 1——
BivatuzumabPhase 1CD44CD44 antigen binding agent
BriquilimabPhase 1KITStem cell growth factor receptor inhibitor
BrontictuzumabPhase 1NOTCH1Neurogenic locus notch homolog protein 1 inhibitor
Cergutuzumab amunaleukinPhase 1——
Cetuximab sarotalocanPhase 1EGFR, Cell membraneEpidermal growth factor receptor erbB1 binding agent
CibisatamabPhase 1——
Citatuzumab bogatoxPhase 1EPCAM, 80S RibosomeEpithelial cell adhesion molecule binding agent
Clivatuzumab tetraxetanPhase 1MUC5ACMucin-5AC binding agent
Cofetuzumab pelidotinPhase 1——
ConatumumabPhase 1TNFRSF10BTumor necrosis factor receptor superfamily member 10B agonist
CrefmirlimabPhase 1——
CrotedumabPhase 1GCGRGlucagon receptor inhibitor
CudarolimabPhase 1——
DatopotamabPhase 1——
DisitamabPhase 1——
ElgemtumabPhase 1ERBB3Receptor tyrosine-protein kinase erbB-3 inhibitor
EluvixtamabPhase 1——
EmerfetamabPhase 1——
EmirodatamabPhase 1——
EnoticumabPhase 1DLL4Delta-like protein 4 inhibitor
EnsituximabPhase 1MUC5ACMucin-5AC other
Epratuzumab 90YPhase 1CD22CD22 binding agent
Fianlimab dfo ZR-89Phase 1——
FlanvotumabPhase 1TYRP15,6-dihydroxyindole-2-carboxylic acid oxidase other
GarivulimabPhase 1——
GatipotuzumabPhase 1MUC1Mucin-1 inhibitor
GatralimabPhase 1——
GentulizumabPhase 1——
GiloralimabPhase 1CD40Tumor necrosis factor receptor superfamily member 5 agonist
GlembatumumabPhase 1GPNMBTransmembrane glycoprotein NMB binding agent
GremubamabPhase 1PCRV, PslLow calcium response locus protein V inhibitor
ImaprelimabPhase 1——
ImvotamabPhase 1——
Indatuximab ravtansinePhase 1SDC1, TubulinSyndecan-1 binding agent
LabetuzumabPhase 1CEACAM5Carcinoembryonic antigen-related cell adhesion molecule 5 other
LetolizumabPhase 1——
LexatumumabPhase 1TNFRSF10BTumor necrosis factor receptor superfamily member 10B agonist
LilotomabPhase 1——
LodapolimabPhase 1——
LonigutamabPhase 1——
LorigerlimabPhase 1——
LucatumumabPhase 1CD40Tumor necrosis factor receptor superfamily member 5 antagonist
LumretuzumabPhase 1ERBB3Receptor tyrosine-protein kinase erbB-3 inhibitor
Luveltamab tazevibulinPhase 1——
Luveltamab tazidePhase 1——
MilatuzumabPhase 1CD74HLA-DR antigens-associated invariant chain antagonist
MinretumomabPhase 1Tumor-associated antigen 72Tumor-associated antigen 72 binding agent
MipasetamabPhase 1——
Mipasetamab uzoptirinePhase 1——
MirzotamabPhase 1——
Mirzotamab clezutoclaxPhase 1——
MitazalimabPhase 1——
ModotuximabPhase 1EGFREpidermal growth factor receptor erbB1 antagonist
Naratuximab emtansinePhase 1CD37Leukocyte antigen CD37 binding agent
NarnatumabPhase 1MST1RMacrophage-stimulating protein receptor inhibitor
NavicixizumabPhase 1——
NidanilimabPhase 1——
NivatrotamabPhase 1——
NurulimabPhase 1——
OcaratuzumabPhase 1MS4A1B-lymphocyte antigen CD20 binding agent
OmburtamabPhase 1——
OmodenbamabPhase 1——
OnvatilimabPhase 1——
OtlertuzumabPhase 1CD37Leukocyte antigen CD37 binding agent
PacanalotamabPhase 1——
PavurutamabPhase 1——
PerakizumabPhase 1IL17AInterleukin 17A inhibitor
PetosemtamabPhase 1——
Pinatuzumab vedotinPhase 1CD22, TubulinCD22 binding agent
PivekimabPhase 1——
PonsegromabPhase 1——
PosdinemabPhase 1MAPTMicrotubule-associated protein tau inhibitor
PraluzatamabPhase 1——
RalpancizumabPhase 1PCSK9Subtilisin/kexin type 9 inhibitor
RevdofilimabPhase 1——
RosmantuzumabPhase 1LGR4, RSPO3RSPO3-LGR4 inhibitor
RunimotamabPhase 1——
SamalizumabPhase 1CD200OX-2 membrane glycoprotein inhibitor
Samrotamab vedotinPhase 1——
SelicrelumabPhase 1CD40Tumor necrosis factor receptor superfamily member 5 agonist
SerclutamabPhase 1——
Serclutamab talirinePhase 1——
SibrotuzumabPhase 1FAPFibroblast activation protein alpha binding agent
Sofituzumab vedotinPhase 1MUC16, TubulinMucin-16 binding agent
StamulumabPhase 1MSTNGrowth/differentiation factor 8 inhibitor
TarcocimabPhase 1——
TarextumabPhase 1NOTCH3, NOTCH2Neurogenic locus notch homolog protein 3 inhibitor
TavolimabPhase 1——
TelisotuzumabPhase 1METHepatocyte growth factor receptor inhibitor
Tetulomab tetraxetan LU-177Phase 1——
TidutamabPhase 1——
TilvestamabPhase 1——
TimolumabPhase 1——
TisotumabPhase 1——
TomaralimabPhase 1TLR2Toll-like receptor 2 antagonist
TomuzotuximabPhase 1EGFREpidermal growth factor receptor erbB1 inhibitor
TosatoxumabPhase 1HLYAlpha-hemolysin inhibitor
TrontinemabPhase 1——
TusamitamabPhase 1——
UbamatamabPhase 1——
UliledlimabPhase 1——
UlocuplumabPhase 1CXCR4C-X-C chemokine receptor type 4 inhibitor
UrabrelimabPhase 1——
Vadastuximab talirinePhase 1——
Vandortuzumab vedotinPhase 1STEAP1, TubulinMetalloreductase STEAP1 binding agent
VantictumabPhase 1FZD1, FZD2, FZD5, FZD7 and 1 moreFrizzled-1 antagonist
VesencumabPhase 1NRP1Neuropilin-1 inhibitor
VofatamabPhase 1FGFR3Fibroblast growth factor receptor 3 inhibitor
Vorsetuzumab mafodotinPhase 1CD70, TubulinCD70 antigen binding agent
VulinacimabPhase 1——
ZiltivekimabPhase 1IL6Interleukin-6 inhibitor
AlsevalimabEarly phase 1——
Actoxumab—TCDAToxin A inhibitor
Afasevikumab—IL17AInterleukin 17A inhibitor
Alacizumab pegol—KDRVascular endothelial growth factor receptor 2 antagonist
Anatumomab mafenatox—TPBGTrophoblast glycoprotein other
Apomab—TNFRSF10BTumor necrosis factor receptor superfamily member 10B agonist
Aselizumab—SELLLeukocyte adhesion molecule-1 inhibitor
Atorolimumab—RHDBlood group Rh(D) polypeptide other
Bectumomab—CD22CD22 other
Bevacizumab 111IN—VEGFAVascular endothelial growth factor A binding agent
Biciromab brallobarbital—FGBFibrinogen beta chain binding agent
Bivatuzumab mertansine—CD44, TubulinCD44 antigen binding agent
Cantuzumab mertansine—MUC1, TubulinMucin-1 binding agent
Capromab—KLK3Prostate specific antigen binding agent
Cedelizumab—CD4T-cell surface antigen CD4 inhibitor
Clenoliximab—CD4T-cell surface antigen CD4 inhibitor
Denintuzumab—CD19B-lymphocyte antigen CD19 binding agent
Dorlimomab aritox—80S Ribosome80S Ribosome inhibitor
Edobacomab—Lipopolysaccharide (LPS)Lipopolysaccharide (LPS) other
Elsilimomab—IL6Interleukin-6 inhibitor
Enapotamab vedotin—Tubulin, AXLTubulin inhibitor
Enavatuzumab—TNFRSF12ATumor necrosis factor receptor superfamily member 12A agonist
Enlimomab—ICAM1Intercellular adhesion molecule-1 inhibitor
Enlimomab pegol—ICAM1Intercellular adhesion molecule-1 antagonist
Epitumomab—MUC1Mucin-1 binding agent
Epitumomab cituxetan—MUC1Mucin-1 binding agent
Erlizumab—ITGB2Integrin beta-2 negative modulator
Faralimomab—IFNA1, IFNA13Interferon alpha-1/13 binding agent
Felvizumab—FFusion glycoprotein F0 inhibitor
Foravirumab—GGlycoprotein inhibitor
Ichorcumab—F2Thrombin inhibitor
Imalumab—MIFMacrophage migration inhibitory factor inhibitor
Keliximab—CD4T-cell surface antigen CD4 negative modulator
Labetuzumab govitecan—CEACAM5, TOP1Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
Lerdelimumab—TGFB2Transforming growth factor beta-2 inhibitor
Losatuxizumab vedotin—Tubulin, EGFRTubulin inhibitor
Maslimomab—T-cell receptorT-cell receptor inhibitor
Metelimumab—TGFB1Transforming growth factor beta-1 inhibitor
Mirvetuximab—FOLR1Folate receptor alpha binding agent
Morolimumab—RHDBlood group Rh(D) polypeptide inhibitor
Nacolomab tafenatox—MUC1Immunostimulant
Nebacumab—Lipopolysaccharide (LPS)Lipopolysaccharide (LPS) inhibitor
Nerelimomab—TNFTNF-alpha inhibitor
Netakimab———
Odulimomab—ITGALLeukocyte adhesion glycoprotein LFA-1 alpha inhibitor
Orticumab—Oxidized LDLOxidized LDL inhibitor
Osocimab—F11Coagulation factor XI negative allosteric modulator
Panobacumab—Lipopolysaccharide (LPS)Lipopolysaccharide (LPS) inhibitor
Pemtumomab—MUC1Mucin-1 binding agent
Priliximab—CD4T-cell surface antigen CD4 negative modulator
Pritumumab—VIMVimentin other
Radretumab—FN1Fibronectin binding agent
Rafivirumab—GGlycoprotein inhibitor
Regavirumab—GBEnvelope glycoprotein B inhibitor
Roledumab—RHDBlood group Rh(D) polypeptide inhibitor
Rovelizumab—ITGAM, ITGB2, ITGAL, ITGB2Integrin alpha-M/beta-2 antagonist
Solitomab—T cell surface glycoprotein CD3, EPCAMT cell surface glycoprotein CD3 cross-linking agent
Sontuzumab—MUC1Mucin-1 other
Tadocizumab—ITGA2B, ITGB3Integrin alpha-IIb/beta-3 antagonist
Talizumab—IGHEIg epsilon chain C region inhibitor
Taplitumomab paptox—CD19, 80S RibosomeB-lymphocyte antigen CD19 binding agent
Tefibazumab—CLFAClumping factor A inhibitor
Tenatumomab—TNCTenascin other
Teneliximab—CD40Tumor necrosis factor receptor superfamily member 5 partial agonist
Toralizumab—CD40LGCD40 ligand inhibitor
Tuvirumab—SMajor surface antigen inhibitor
Urtoxazumab—STXBShiga toxin subunit B inhibitor
Vepalimomab—AOC3Amine oxidase, copper containing inhibitor
Vorsetuzumab—CD70CD70 antigen binding agent
Ziralimumab—BSGBasigin inhibitor
Zolimomab aritox—CD5, 80S RibosomeT-cell surface glycoprotein CD5 binding agent
AnivovetmabPhase 2——
TirnovetmabPhase 1——
Bedinvetmab—NGFBeta-nerve growth factor binding agent
Frunevetmab—NGFBeta-nerve growth factor binding agent
Lokivetmab—IL31Interleukin 31 binding agent

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.